Market Intelligence, Clinical Progress, and High-Purity Reagents for Integrated Stress Response (ISR) and Hemoglobinopathy Drug Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for EIF2AK1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen / Target Protein | EIF2AK1 Recombinant Protein (Kinase Domain / Full Length) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View EIF2AK1 Products |
| Gene Delivery | EIF2AK1 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and cellular phosphorylation assays. |
View EIF2AK1 Products |
| Benchmark Ab | Anti-EIF2AK1 Recombinant Antibody Recombinant positive control for Western Blot and ELISA validation. |
View EIF2AK1 Products |
| Validator | EIF2AK1 siRNA Set For target knockdown and specificity verification in cellular assays. |
View EIF2AK1 Products |
| Related Target A | EIF2S1 (eIF2α) Direct physiological substrate of EIF2AK1; critical for kinase activity assays. |
View EIF2S1 Products |
| Related Target B | ATF4 Downstream transcription factor upregulated via EIF2AK1-mediated translation control. |
View ATF4 Products |
| Related Target C | EIF2AK3 (PERK) Homologous eIF2α kinase; essential for selectivity and off-target screening panels. |
View EIF2AK3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Kinase Selectivity (Avoiding PERK/PKR/GCN2 cross-reactivity) | Recombinant homologous kinase panels available with strictly verified sequence identity. |
| Physiological Substrate Phosphorylation Detection | High-purity EIF2S1 (eIF2α) substrate proteins engineered for optimal in vitro kinase assays. |
| Lack of Controls for Validation | Sequence-verified clinical benchmark antibodies and siRNA sets included in the portfolio. |
| Cellular Context Phosphorylation Verification | Lentiviral vectors optimized for stable overexpression of WT and kinase-dead EIF2AK1 mutants. |
Live EIF2AK1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic modulation of EIF2AK1 (Heme-Regulated Inhibitor, HRI) is gaining significant traction across multiple indications, most notably in hemoglobinopathies (such as Beta-Thalassemia and Sickle Cell Disease) and oncology. As a key upstream sensor of the Integrated Stress Response (ISR), EIF2AK1 regulates protein translation under proteotoxic and nutritional stress. Inhibiting EIF2AK1 prevents the phosphorylation of eIF2α, thereby sustaining globin synthesis or sensitizing stressed cancer cells to proteasome inhibitors. Conversely, small-molecule activators of EIF2AK1 are being explored to induce fetal hemoglobin (HbF) and alleviate sickling disorders. The next wave of R&D is highly focused on achieving extreme selectivity over other eIF2α kinases (PERK, PKR, GCN2) to avoid systemic toxicities, requiring rigorous biochemical and cellular screening platforms.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Agios Pharmaceuticals, Vertex Pharmaceuticals | Beta-Thalassemia, Sickle Cell Disease | High-throughput Kinase Profiling (Need active EIF2AK1 recombinant kinase domain) |
| Small Molecule Activators | Academic Consortia, Biotech Startups | Hemoglobinopathies, Solid Tumors | Cellular ISR Activation Assays (Need EIF2AK1 Lentivirus for stable reporter lines) |
| RNA Therapeutics / siRNA | Alnylam, Ionis Pharmaceuticals | Hematological Disorders, Oncology | Target Knockdown Validation (Need validated EIF2AK1 siRNA and reference antibodies) |